
    
      The study is open label and has one treatment group. Eligible HCV GT1 subjects will self
      administer orally 400 mg of CDI-31244 and fixed dose combination of sofosbuvir and
      velpatasvir for 14 days. After 14 days the subjects will continue the treatment for another 4
      weeks on the fixed dose combination sofosbuvir and velpatasvir. The subjects will be followed
      up until 24 weeks after the last dose of sofosbuvir and velpatasvir to determine if sustained
      virologic response at 12 (SVR12) and 24 (SVR24) weeks after treatment have been achieved.
    
  